Preclinical Efficacy and Intermediate Endpoint Biomarkers contract IDIQ-HHS-PEIEB-15 Master IDIQ
POP 9/20/12 - 9/19/14 (1 year)
Master IDIQ for evaluating the efficacy of potential chemopreventive regimens as well as to identifypharmacodynamic and or efficacy biomarkers which will enhance the development of these regimens for clinicaltrials.
- $9.6m Aggregate Dollars Obligated
- $9.6m Aggregate Base & Exercised Options
- $9.6m Aggregate Base & All Options (Ceiling)